Future Today’s genomic medicine

Drs. Topol, Schork and Murray of the Scripps Translational Science Institute were recently interviewed following the 3rd annual Future of Genomic Medicine Conference (FoGMIII, cosponsored by Scripps and the J. Craig Venter Institute, and held March 5 and 6 in San Diego, California.).

Medscape Interviews can be found here:

Topol Medscape Interview MAR2010

Schork Medscape Interview MAR2010

Murray Medscape Interview MAR2010

Dr Eric Topol’s excerpts: Leroy Hood, Miller’s syndrome and whole-genome sequencing on family members, Elaine Mardis and cancer genomics efforts in 50 paired sequencings in patients with breast cancer, PacBio and the 2010 $5000-$6000 genome, Greg Lucier and Life Technologies funding education in genomic medicine education, and Eric’s work on aging and 4EBP, insulin-like growth factor (IGF)-1 signaling, TOR (target of rapamycin) signaling, and mitochondrial energy.

Dr Nicholas J. Schork’s excerpts: Invasive vs non-invasive MRSA genetics, the microbiome and genomic medicine (our favorite, dedicated to the French geneticians community)

“… If physicians don’t want to buy into genomic medicine, they’re going to be swept over with this massive tidal wave of findings and clinically relevant insights. It really behooves the clinical community to pay attention to this stuff.”

Dr Sarah S. Murray’s excerpts: “…My particular talk last year was on areas where there were holes in our knowledge, pointing out the great strides GWAS studies have made, but also where some of the limitations are. I think now the field is shifting focus into sequencing, as well, to help fill some of those holes, going after more rare variation and its role in disease…”, aging and the “canonical” pathways for lifespan with Andy Dillin, Nir Barzilai, Doug Wallace and Eric Topol, and where the field is with being able to do risk prediction based primarily on markers from genome-wide association studies:

“…The take-home message is that there are obviously a lot of limitations, but there are cases where there is some utility. The hope is that as we’re starting to identify genetic risk factors that actually have larger effects, and we are starting to see those. The presumption is that the prediction will improve.”